A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years

Arch Ophthalmol. 2008 Aug;126(8):1039-44. doi: 10.1001/archopht.126.8.1039.

Abstract

Objective: To determine the visual acuity outcome at age 10 years for children younger than 7 years when enrolled in a treatment trial for moderate amblyopia.

Methods: In a multicenter clinical trial, 419 children with amblyopia (visual acuity, 20/40-20/100) were randomized to patching or atropine eyedrops for 6 months. Two years after enrollment, a subgroup of 188 children entered long-term follow-up. Treatment after 6 months was at the discretion of the investigator; 89% of children were treated.

Main outcome measure: Visual acuity at age 10 years with the electronic Early Treatment Diabetic Retinopathy Study test.

Application to clinical practice: Patching and atropine eyedrops produce comparable improvement in visual acuity that is maintained through age 10 years.

Results: The mean amblyopic eye acuity, measured in 169 patients, at age 10 years was 0.17 logMAR (logarithm of the minimum angle of resolution) (approximately 20/32), and 46% of amblyopic eyes had an acuity of 20/25 or better. Age younger than 5 years at entry into the randomized trial was associated with a better visual acuity outcome (P < .001). Mean amblyopic and sound eye visual acuities at age 10 years were similar in the original treatment groups (P = .56 and P = .80, respectively).

Conclusions: At age 10 years, the improvement of the amblyopic eye is maintained, although residual amblyopia is common after treatment initiated at age 3 years to younger than 7 years. The outcome is similar regardless of initial treatment with atropine or patching.

Trial registration: ClinicalTrials.gov NCT00000170.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Amblyopia / physiopathology
  • Amblyopia / therapy*
  • Atropine / administration & dosage
  • Atropine / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Mydriatics / administration & dosage
  • Mydriatics / therapeutic use*
  • Refraction, Ocular / physiology
  • Sensory Deprivation*
  • Treatment Outcome
  • Vision, Binocular / physiology
  • Visual Acuity / physiology

Substances

  • Mydriatics
  • Atropine

Associated data

  • ClinicalTrials.gov/NCT00000170